Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,896 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study.
Hu J, Chen J, Ou Z, Chen H, Liu Z, Chen M, Zhang R, Yu A, Cao R, Zhang E, Guo X, Peng B, Deng D, Cheng C, Liu J, Li H, Zou Y, Deng R, Qin G, Li W, Wang L, Chen T, Pei X, Gong G, Tang J, Othmane B, Cai Z, Zhang C, Liu Z, Zu X. Hu J, et al. Among authors: gong g. Cell Rep Med. 2022 Nov 15;3(11):100785. doi: 10.1016/j.xcrm.2022.100785. Epub 2022 Oct 19. Cell Rep Med. 2022. PMID: 36265483 Free PMC article.
[Surgical treatment for mitral valve prolapse].
Zhang DC, Gong GF, Hu JG. Zhang DC, et al. Among authors: gong gf. Hunan Yi Ke Da Xue Xue Bao. 2000 Feb 28;25(1):68-70. Hunan Yi Ke Da Xue Xue Bao. 2000. PMID: 12212256 Clinical Trial. Chinese.
Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.
Chen J, Wang L, Tang Y, Gong G, Liu L, Chen M, Chen Z, Cui Y, Li C, Cheng X, Qi L, Zu X. Chen J, et al. Among authors: gong g. J Exp Clin Cancer Res. 2016 Jan 6;35:2. doi: 10.1186/s13046-015-0282-y. J Exp Clin Cancer Res. 2016. PMID: 26733306 Free PMC article.
N6-Methyladenosine in Cancer Immunotherapy: An Undervalued Therapeutic Target.
Quan C, Belaydi O, Hu J, Li H, Yu A, Liu P, Yi Z, Qiu D, Ren W, Ma H, Gong G, Ou Z, Chen M, Sun Y, Chen J, Zu X. Quan C, et al. Among authors: gong g. Front Immunol. 2021 Aug 30;12:697026. doi: 10.3389/fimmu.2021.697026. eCollection 2021. Front Immunol. 2021. PMID: 34526985 Free PMC article. Review.
1,896 results